{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:17:01Z","timestamp":1788254221934,"version":"build-2803163510"},"reference-count":168,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Immune checkpoint inhibitors have revolutionized the treatment of advanced melanoma, yet primary and acquired resistance remain major barriers to durable disease control. This narrative review examines the clinical patterns, biological mechanisms, biomarker limitations, and therapeutic implications of immunotherapy failure. Methods: A structured search of PubMed, Web of Science, and ClinicalTrials.gov identified relevant studies published from January 2010 to May 2026, supplemented by landmark earlier reports. Results: Immunotherapy resistance encompasses heterogeneous patterns, including early progression, oligoprogression, dissociated response, brain-dominant progression, relapse after response, and progression after treatment discontinuation. These clinical phenotypes arise from overlapping mechanisms such as loss of antigen presentation, impaired interferon signaling, oncogenic immune exclusion, melanoma dedifferentiation, suppressive myeloid and regulatory T-cell programs, stromal and vascular barriers, metabolic restriction, and deterioration of tumor-reactive T-cell clones. Conventional response criteria and static biomarkers, including PD-L1 expression and tumor mutational burden, do not adequately capture this complexity because resistance varies across lesions and evolves under treatment pressure. Negative trials of IDO1 inhibition, cytokine intensification, vaccines, and intratumoral immune stimulation further show that biological plausibility and early activity do not guarantee clinical benefit when target engagement, patient enrichment, and endpoint selection are inadequate. Conclusions: Immunotherapy resistance in melanoma should be viewed as a variety of biologically distinct clinical states rather than a single endpoint. Future progress will require resistance-matched treatment, longitudinal tissue and circulating tumor DNA assessment, adaptive trial designs, and endpoints aligned with treatment kinetics. This framework may improve salvage selection and interpretation of post-PD-1 studies in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers18172829","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"2829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Immunotherapy Resistance in Melanoma: A Narrative Review of Clinical Patterns, Resistance Mechanisms, and Future Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7254-4261","authenticated-orcid":false,"given":"Ali","family":"Ghais","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-5866","authenticated-orcid":false,"given":"Joe","family":"Rizkallah","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7446-4312","authenticated-orcid":false,"given":"Bahaa El Deen","family":"Wehbeh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8588-9053","authenticated-orcid":false,"given":"Youssef","family":"Diab","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Awada","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Atwi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Mina","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6131-0955","authenticated-orcid":false,"given":"Firas","family":"Rammal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Badr","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-8365","authenticated-orcid":false,"given":"Sary","family":"Faraj","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7877-3086","authenticated-orcid":false,"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-5154","authenticated-orcid":false,"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113441","DOI":"10.1016\/j.ejca.2023.113441","article-title":"The features and management of acquired resistance to PD1-based therapy in metastatic melanoma","volume":"196","author":"Hepner","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable Complete Response After Discontinuation of Pembrolizumab in Patients with Metastatic Melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e001781","DOI":"10.1136\/jitc-2020-001781","article-title":"Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma","volume":"9","author":"Pokorny","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Humbert, O., and Chardin, D. (2020). Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight with Immunotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.566297"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.04.003","article-title":"The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis","volume":"151","author":"Versluis","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: A US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s40425-019-0672-3","article-title":"Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma","volume":"7","author":"Klemen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"Ismail","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2015656","DOI":"10.1001\/jamanetworkopen.2020.15656","article-title":"Association of Sociodemographic Factors with Immunotherapy Receipt for Metastatic Melanoma in the US","volume":"3","author":"Moyers","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.36401\/JIPO-23-X1","article-title":"Learning From Failure: Negative Trials in Oncology","volume":"6","author":"Nardo","year":"2023","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-020-02716-3","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00262-023-03581-6","article-title":"Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma","volume":"73","author":"Versluis","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.1002\/cam4.4342","article-title":"Value of screening and follow-up brain MRI scans in patients with metastatic melanoma","volume":"10","author":"Eggen","year":"2021","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100598","DOI":"10.1016\/j.esmoop.2022.100598","article-title":"How I treat brain metastases of melanoma","volume":"7","author":"Eroglu","year":"2022","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients with Advanced Melanoma Treated with Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s00330-024-11060-4","article-title":"Real-world response assessment of immune checkpoint inhibition: Comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients","volume":"35","author":"Nelles","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e16417","DOI":"10.1097\/MD.0000000000016417","article-title":"Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET\/CT in patients with melanoma","volume":"98","author":"Amrane","year":"2019","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis","volume":"297","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","article-title":"Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial","volume":"31","author":"Ahmed","year":"2021","journal-title":"Eur. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e3997","DOI":"10.1097\/MD.0000000000003997","article-title":"Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials","volume":"95","author":"Petrelli","year":"2016","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: Current challenges and future prospect","volume":"10","author":"Adelantado","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_40","unstructured":"(2015). The Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","article-title":"A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma","volume":"187","author":"Pozniak","year":"2024","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fitzsimmons, T.S., Singh, N., Walker, T.D.J., Newton, C., Evans, D.G.R., Crosbie, E.J., and Ryan, N.A.J. (2023). Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: A systematic review and meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1192762"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Racacho, K.J., Shiau, Y.P., Villa, R., Mahri, S., Tang, M., Lin, T.Y., and Li, Y. (2025). The tumor immune microenvironment: Implications for cancer immunotherapy, treatment strategies, and monitoring approaches. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1621812"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","article-title":"Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction","volume":"29","author":"Mlecnik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: The mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mlynska, A., Gibavi\u010dien\u0117, J., Kutanovait\u0117, O., Senkus, L., Ma\u017eeikait\u0117, J., Ker\u0161evi\u010di\u016bt\u0117, I., Maskoli\u016bnait\u0117, V., Rupeikait\u0117, N., Sabaliauskait\u0117, R., and Gai\u017eevska, J. (2024). Defining Melanoma Immune Biomarkers\u2014Desert, Excluded, and Inflamed Subtypes\u2014Using a Gene Expression Classifier Reflecting Intratumoral Immune Response and Stromal Patterns. Biomolecules, 14.","DOI":"10.3390\/biom14020171"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Grell, P., Borilova, S., Fabian, P., Selingerova, I., Novak, D., Muller, P., Kiss, I., and Vyzula, R. (2023). FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061901"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40257-024-00907-7","article-title":"Overcoming Resistance Mechanisms to Melanoma Immunotherapy","volume":"26","author":"Zheng","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/cr.2017.34","article-title":"Blocking the recruitment of naive CD4(+) T cells reverses immunosuppression in breast cancer","volume":"27","author":"Su","year":"2017","journal-title":"Cell Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Goldmann, O., Nwofor, O.V., Chen, Q., and Medina, E. (2024). Mechanisms underlying immunosuppression by regulatory cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1328193"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1172\/JCI36604","article-title":"PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV","volume":"119","author":"Franceschini","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Qiao, G., He, H., and Wang, X. (2025). CD39(+)PD-1(+) regulatory T cells in melanoma: Key drivers of systemic immunosuppression and prognostic biomarkers. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1724062"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41551-021-00766-1","article-title":"Solid stress impairs lymphocyte infiltration into lymph-node metastases","volume":"5","author":"Jones","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","article-title":"The role of mechanical forces in tumor growth and therapy","volume":"16","author":"Jain","year":"2014","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Monteran, L., and Erez, N. (2019). The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01835"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e006401","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.acr.2015.05.001","article-title":"Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment","volume":"128","author":"Peske","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","article-title":"Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors","volume":"108","author":"Donnadieu","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic Barriers to T Cell Function in Tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4049\/immunohorizons.1900017","article-title":"Intratumoral Hypoxia Reduces IFN-\u03b3-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model","volume":"3","author":"Murthy","year":"2019","journal-title":"Immunohorizons"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e170762","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: Myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Lasser","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-017-1988-9","article-title":"CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma","volume":"66","author":"Umansky","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Petrova, V., Groth, C., Bitsch, R., Arkhypov, I., Simon, S.C.S., Hetjens, S., M\u00fcller, V., Utikal, J., and Umansky, V. (2023). Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1065767"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/1744666X.2024.2326626","article-title":"Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma","volume":"20","author":"Habib","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2127284","DOI":"10.1080\/2162402X.2022.2127284","article-title":"Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies","volume":"11","author":"Adams","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3892\/etm.2022.11577","article-title":"Macrophages in melanoma: A double-edged sword and targeted therapy strategies (Review)","volume":"24","author":"Zhou","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1080\/21645515.2017.1312043","article-title":"Pro-tumor activities of macrophages in the progression of melanoma","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: Frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e011030","DOI":"10.1136\/jitc-2024-011030","article-title":"Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming","volume":"13","author":"Takahashi","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1846915","DOI":"10.1080\/2162402X.2020.1846915","article-title":"MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma","volume":"9","author":"Shoshan","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ceci, C., Atzori, M.G., Lacal, P.M., and Graziani, G. (2020). Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12113401"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"100842","DOI":"10.1016\/j.xgen.2025.100842","article-title":"Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy","volume":"5","author":"Shorer","year":"2025","journal-title":"Cell Genom."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100373","DOI":"10.1016\/j.iotech.2023.100373","article-title":"TCR sequencing: Applications in immuno-oncology research","volume":"17","author":"Joshi","year":"2023","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2102849118","DOI":"10.1073\/pnas.2102849118","article-title":"Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response","volume":"118","author":"Gangaev","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e81952","DOI":"10.7554\/eLife.81952","article-title":"T cell receptor convergence is an indicator of antigen-specific T cell response in cancer immunotherapies","volume":"11","author":"Pan","year":"2022","journal-title":"Elife"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Yosri, M., Dokhan, M., Aboagye, E., Al Moussawy, M., and Abdelsamed, H.A. (2024). Mechanisms governing bystander activation of T cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1465889"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Manne","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","article-title":"Evolution of delayed resistance to immunotherapy in a melanoma responder","volume":"27","author":"Liu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1078-0432.CCR-23-0099","article-title":"HLA Class II Loss and JAK1\/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFN\u03b3 Cross-Resistance","volume":"29","author":"Stupia","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2595360","DOI":"10.1080\/2162402X.2025.2595360","article-title":"Wnt3a-expressing cancer stem cells impair CD8(+)\u2009TRM function, contributing to immunotherapy resistance in Melanoma","volume":"14","author":"Bonifaz","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_108","first-page":"100532","article-title":"Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma","volume":"26","author":"Parra","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaax7918","DOI":"10.1126\/scitranslmed.aax7918","article-title":"Neoantigen quality, not quantity","volume":"11","author":"McGranahan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/1078-0432.CCR-23-0824","article-title":"Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers","volume":"31","author":"Niknafs","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Pikturniene, R., Cesas, A., Jarmalaite, S., Razbadauskas, A., and Urbonas, V. (2024). Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions. Cancers, 16.","DOI":"10.3390\/cancers16061197"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Magbanua, M.J.M., Li, W., and van \u2019t Veer, L.J. (2024). Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes. Cancers, 16.","DOI":"10.3390\/cancers16101879"},{"key":"ref_124","first-page":"259","article-title":"Circulating tumor DNA in patients with cancer: Insights from clinical laboratory","volume":"6","author":"Illana","year":"2025","journal-title":"Adv. Lab. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Gschwind, A., and Ossowski, S. (2025). AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers. Cancers, 17.","DOI":"10.20944\/preprints202501.0904.v1"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/1078-0432.CCR-21-3114","article-title":"Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients\u2019 Response to Anti-PD-1 Immune Checkpoint Blockade","volume":"28","author":"Triozzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Lei, Y., Li, X., Huang, Q., Zheng, X., and Liu, M. (2021). Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.617335"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Qin, J.J., Wang, Y., and Sandhu, S. (2026). mRNA and Peptide Vaccines in Melanoma\u2014Current Landscape and Future Direction. Cells, 15.","DOI":"10.3390\/cells15040344"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e70400","DOI":"10.1002\/cncr.70400","article-title":"Updates on intratumoral therapies in melanoma","volume":"132","author":"Ma","year":"2026","journal-title":"Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.21.00675","article-title":"Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma","volume":"39","author":"Diab","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-16-3079","article-title":"Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies","volume":"23","author":"Siu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: The current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward Minimal Residual Disease-Directed Therapy in Melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_158","first-page":"42","article-title":"Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma","volume":"7","author":"Jalil","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"116595","DOI":"10.1016\/j.ejca.2026.116595","article-title":"Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients\u2014A retrospective DeCOG study","volume":"237","author":"Albrecht","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a First-in-Class PI3K\u03b3 Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1\/1b MARIO-1 Trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2688603","DOI":"10.1080\/2162402X.2026.2688603","article-title":"Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma","volume":"15","author":"Najjar","year":"2026","journal-title":"Oncoimmunology"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Herbreteau, G., Vall\u00e9e, A., Knol, A.C., Th\u00e9oleyre, S., Qu\u00e9reux, G., Varey, E., Khammari, A., Dr\u00e9no, B., and Denis, M.G. (2021). Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers, 13.","DOI":"10.3390\/cancers13081826"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Ballesteros, P.A., Chamorro, J., Roman-Gil, M.S., Pozas, J., Gomez Dos Santos, V., Granados, A.R., Grande, E., Alonso-Gordoa, T., and Molina-Cerrillo, J. (2021). Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13235981"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/14737140.2020.1745634","article-title":"Melanoma immunotherapy: Strategies to overcome pharmacological resistance","volume":"20","author":"Trojaniello","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:39:14Z","timestamp":1788251954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":168,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172829"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172829","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}